New FDA/NIH Course Aims to Improve How Gov’t Designs, Evaluates ‘Smaller’ Trials | GenomeWeb
The US Food and Drug Administration and the National Institutes of Health will hold a course in January designed to improve how their employees design and evaluate small-scale clinical trials for rare diseases.
“Although no part of the course addresses genomics directly, the design/analysis methods [that will be] discussed are of use in a wide variety of circumstances, genomics included,” a spokesperson from the Office of Orphan Products told Pharmacogenomics Reporter this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.